fr | en
Micro et Nanomédecines translationnelles

2 post-doc positions open at labMint

POST-DOC in Polymer or Organic Chemistry

Lipid nanocapsules based on polyoxazolines for drug delivery and diagnostic (LNC-Pox)Visualiser le fichier «FICHE_POSTE_POST-DOC_MINT-1.pdf» en ligne
The project will focus on the development of polymeric materials to meet the needs of medicine for diagnostic and therapeutic approaches, essentially in cancer treatment. The development of new Drug Delivery Systems (DDS) has potential in multiple targeting functionalization, in vitro and in vivo imaging, with the incorporation of stimulus-responsive materials. In this context, polymers represent an important class of materials that can be used for the preparation of organic DDS due to their abilities to encapsulate and to respond to specific stimuli in order to deliver the drug to a targeted region. In this context, stimuli-responsive polymers known as “smart materials” have greater potential than traditional delivery systems as they can respond to internal or external stimuli to potentiate the efficacy of the nanomedicine.
The project will focus on development of Drug Delivery Systems as Lipid NanoCapsules (LNCs) based on new amphiphilic polymers possessing fluorescent probes as markers.
Provisional project schedule: May 2023– October 2024 (more information) contact : (mireille.loirat @


The NEMESIS project: nanoparticle engineering for miRNA delivery in intervertebral disc regenerative strategiesVisualiser le fichier «Postdoc ANR Nemesis_Eng.pdf» en ligne

The degeneration of the intervertebral disc (IVD), at the origin of many cases of low back pain, is characterized by a degradation of the IVD extracellular matrix and a loss of IVD role in spine kinematics. There is currently no etiological treatment for these disorders. Our better understanding of the role of microRNAs (miR) in the physiopathology of IVDs allow to explore their use as therapeutics. miR are easily degraded and must be protected to reach their target. The NEMESIS project thus aims to develop peptide-functionalized lipid nanocapsules (fLNC) for the intradiscal delivery of miR155. The fLNC-miR155 will be successively produced, characterized and then tested in vitro, ex vivo and in vivo in a preclinical model of IVD degeneration in sheep. Finally, a clinical trial in dogs with chronic discogenic low back pain will
be conducted to provide clinical proof of this new concept. NEMESIS will associate 2 INSERM laboratories and the veterinary school of Nantes. ANR PRC project obtained in July 2022 with RMeS laboratory and Prof J. Clouet as project leader, and MINT laboratory and Dr. E. Lepeltier as partner.

contact: and